:internalReference - plerixafor | 110078-46-1

Stability Hygroscopic
Applications Plerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). This agent was approved on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Selective CXCR4 antagonist.
References Xie, T., et al.: Science, 290, 328 (2000), Leone, D., et al.: J. Pharmacol. Exp. Ther., 305, 1150 (2003), Chigaev, A., et al.: J. Immunol. 178, 6828 (2007), Kiel, M., et al.: Cell Stem Cell, 1, 204 (2007),

Initially identified as a selective inhibitor of HIV-1 and HIV-2 replication. This activity was ascribed to the specific binding to chemokine receptor CXCR4 and inhibition of its signaling downstream, mediated by SDF-1. Antagonizes binding of CXCL12 to CXCR4, inducing mobilization of hematopoietic progenitor cells that is enhanced in synergy with G-CSF.